Cover Image
市場調查報告書

神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) :開發中產品分析

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365748
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) :開發中產品分析 Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 95 Pages
簡介

本報告提供以神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) 為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經性乙醯膽鹼受體 亞單位α7 (CHRNA7) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bionomics Limited
  • Catalyst Biosciences, Inc.
  • CoMentis, Inc.
  • FORUM Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • NeuroDerm Ltd.
  • Neurodyn Inc.
  • Pfizer Inc.
  • Saniona AB
  • SK Biopharmaceuticals Co., Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0192TDB

Summary

Global Markets Direct's, 'Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H1 2016', provides in depth analysis on Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted pipeline therapeutics.

The report provides comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Overview
  • Therapeutics Development
    • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Stage of Development
    • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Therapy Area
    • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Indication
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Companies
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
    • Bionomics Limited
    • Catalyst Biosciences, Inc.
    • CoMentis, Inc.
    • FORUM Pharmaceuticals Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • NeuroDerm Ltd.
    • Neurodyn Inc.
    • Pfizer Inc.
    • Saniona AB
    • SK Biopharmaceuticals Co., Ltd.
    • Sunovion Pharmaceuticals Inc.
    • Vanda Pharmaceuticals Inc.
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
    • (nicotine + opipramol hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APN-1125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQW-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-8168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-375 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer's Disease and Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-3748 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • encenicline hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FRM-17874 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gln-1062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTS-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-39393406 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NBP-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNU-120596 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-15508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-A4R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TC-7020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Projects
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Featured News & Press Releases
    • Mar 24, 2016: FORUM Pharmaceuticals Provides Update on Encenicline Phase 3 Clinical Trial Program in Cognitive Impairment in Schizophrenia
    • Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
    • Nov 11, 2015: FORUM Pharmaceuticals Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program for Cognitive Impairment in Schizophrenia
    • Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression
    • Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer's Disease and Cognitive Impairment in Schizophrenia
    • Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia
    • Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia
    • Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia
    • Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety
    • Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210
    • Jan 09, 2015: CoMentis and Anvyl Announce the Initiation of Clinical Trials for APN1125 for the Treatment of Schizophrenia
    • Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting
    • Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials
    • Sep 09, 2014: Positive Phase 1a Outcome for Memogain
    • Feb 21, 2014: Neurodyn creates Memogain Advisory Board
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Bionomics Limited, H1 2016
  • Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Pipeline by CoMentis, Inc., H1 2016
  • Pipeline by FORUM Pharmaceuticals Inc., H1 2016
  • Pipeline by Johnson & Johnson, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by NeuroDerm Ltd., H1 2016
  • Pipeline by Neurodyn Inc., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Saniona AB, H1 2016
  • Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Pipeline by Sunovion Pharmaceuticals Inc., H1 2016
  • Pipeline by Vanda Pharmaceuticals Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top